A phase II study investigating safety and efficacy of dose reduced fludarabine, cyclophosphamide and obinutuzumab versus chlorambucil and obinutuzumab in untreated, comorbid, elderly patients with chronic lymphocytic leukemia (CLL)

被引：0
|
作者：
Mulligan, Stephen [1 ,2 ]
Tam, Constantine [1 ,2 ]
Badoux, Xavier [1 ,2 ]
Kuss, Bryone [1 ,2 ]
机构：
[1] Australasian Leukaemia & Lymphoma Grp, Richmond, VI, Australia
[2] CLL Australian Res Consortium, Richmond, VI, Australia
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
32
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [1] Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study
    Leblond, Veronique
    Cantin, Guy
    Cortelezzi, Agostino
    Knauf, Wolfgang
    Tiab, Mourad
    Turgut, Mehmet
    Zaritskey, Andrey
    Merot, Jean-Louis
    Trunzer, Kerstin
    Robson, Susan
    Gresko, Ekaterina
    Stilgenbauer, Stephan
    Foa, Robin
    Bosch, Francesc
    BLOOD, 2017, 130
  • [2] Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC plus G) Versus Chlorambucil Plus Obinutuzumab (Cbl plus G) As Front-Line Therapy
    Mulligan, Stephen P.
    Freeman, Jane A.
    Badoux, Xavier
    Eek, Richard
    Cull, Gavin
    Mackinlay, Naomi J.
    Murphy, Nicholas E.
    Carradice, Duncan P.
    Solterbeck, Ann C.
    Best, Oliver Giles
    Tam, Constantine S.
    Kuss, Bryone J.
    BLOOD, 2018, 132
  • [3] Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Lampson, Benjamin L.
    Tyekucheva, Svitlana
    Crombie, Jennifer L.
    Kim, Austin I.
    Merryman, Reid W.
    Lowney, Jessica
    Montegaard, Josie
    Patterson, Victoria
    Jacobson, Caron A.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Arnason, Jon E.
    Armand, Philippe
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    BLOOD, 2019, 134
  • [4] Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
    Bosch, Francesc
    Cantin, Guy
    Cortelezzi, Agostino
    Knauf, Wolfgang
    Tiab, Mourad
    Turgut, Mehmet
    Zaritskey, Andrey
    Merot, Jean-Louis
    Tausch, Eugen
    Trunzer, Kerstin
    Robson, Susan
    Gresko, Ekaterina
    Boettcher, Sebastian
    Foa, Robin
    Stilgenbauer, Stephan
    Leblond, Veronique
    LEUKEMIA, 2020, 34 (02) : 441 - 450
  • [5] Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
    Francesc Bosch
    Guy Cantin
    Agostino Cortelezzi
    Wolfgang Knauf
    Mourad Tiab
    Mehmet Turgut
    Andrey Zaritskey
    Jean-Louis Merot
    Eugen Tausch
    Kerstin Trunzer
    Susan Robson
    Ekaterina Gresko
    Sebastian Böttcher
    Robin Foà
    Stephan Stilgenbauer
    Véronique Leblond
    Leukemia, 2020, 34 : 441 - 450
  • [6] Elevate Tn Phase 3 Study of Acalabrutinib Plus Obinutuzumab or Acalabrutinib Monotherapy vs Chlorambucil Plus Obinutuzumab (ClbO) in Subjects with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Martens, Uwe
    Sharman, Jeff
    Banerji, Versha
    Fogliatto, Laura Maria
    Herishanus, Yair
    Munir, Talha
    Walewska, Renato
    Follows, George
    Karlsson, Karin
    Ghia, Paolo
    Corbett, Gillian
    Walker, Patricia
    Egyed, Miklos
    Jurczak, Wojciech
    Salles, Gilles
    Janssens, Ann
    Cymbalista, Florence
    Wierda, William
    Coutre, Steven E.
    Pagel, John M.
    Skarbnik, Alan P.
    Kamdar, Manali
    Izumi, Raquel
    Munugala, Veerendra
    Patel, Priti
    Wang, Min Hui
    Wong, Sofia
    Woyach, Jennifer
    Byrd, John
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 127 - 127
  • [7] Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL).
    Sharman, Jeff Porter
    Yimer, Habte Aragaw
    Boxer, Michael
    DiBella, Nicholas
    Babu, Sunil
    Li, Jia
    Mun, . . . Yong Jun
    Skettino, Sandra L.
    Danilov, Alexey Valeryevich
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] OBINUTUZUMAB IN COMBINATION WITH CHLORAMBUCIL IN THE FIRST LINE OF TREATMENT OF ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Markova, E. E.
    Nikitin, E. A.
    Dmitrieva, E. A.
    Mayorova, S. Yu
    Kochkareva, Yu B.
    Naumova, E., V
    Lugovskaya, S. A.
    Pochtar, M. E.
    Petrenko, A. A.
    Kislova, M., I
    Biderman, B., V
    Sudarikov, A. B.
    Obukhova, T. N.
    Ptushkin, V. V.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2022, 67 (04): : 478 - 490
  • [9] A phase Ib/II study of obinutuzumab and high-dose methylprednisolone (HDMP) for therapy of patients with chronic lymphocytic leukemia (CLL)
    Castro, Januario
    Choi, Michael Y.
    Amaya-Chanaga, Carlos I.
    Nguyen, Natalie
    Ale-Ali, Amine
    Kipps, Thomas J.
    LEUKEMIA & LYMPHOMA, 2015, 56 : 18 - 19
  • [10] OBINUTUZUMAB PLUS CHLORAMBUCIL VERSUS IBRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT TP53 DISRUPTIONS. A CAMPUS CLL STUDY
    Visentin, A.
    Pravato, S.
    Mauro, F. R.
    Pietrasanta, D.
    Fresa, A.
    Vitale, C.
    Ciolli, S.
    Cassin, R.
    Cibien, F.
    Sportoletti, P.
    Gentile, M.
    Rigolin, G. M.
    Quaglia, F. M.
    Murru, R.
    Gozzetti, A.
    Molica, S.
    Marchetti, M.
    Scarfo, L.
    Guardalben, E.
    Avitabile, A.
    Reda, G.
    Coscia, M.
    Laurenti, L.
    Pizzolo, G.
    Semenzato, G.
    Foa, R.
    Cuneo, A.
    Trentin, L.
    HAEMATOLOGICA, 2021, 106 (10) : 62 - 63
12345